A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer models
Stefan Mrđenović(Cedars-Sinai Medical Center), Yi Zhang(Tianjin Medical University General Hospital), Edwin M. Posadas(Cedars-Sinai Medical Center), Stephen J. Pandol(Cedars-Sinai Medical Center), Marija Heffer(University of Osijek), Mouad Edderkaoui(Cedars-Sinai Medical Center), Michael Lewis, Yanping Wang(Loyola University Medical Center), Lijuan Yin(Tianjin University of Science and Technology), Yan Ou(Cedars-Sinai Medical Center), Gina Chia‐Yi Chu(Multimeric Biotherapeutics (United States)), Leland W.K. Chung(VA Palo Alto Health Care System), Haiyen E. Zhau(Cedars-Sinai Medical Center), Ruoxiang Wang(Cedars-Sinai Medical Center)
Cited by 6
Related Papers
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
|The Lancet|2020|29.1k
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
|Cellular Physiology and Biochemistry|2017|4.1k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Roles of IFN-γ in tumor progression and regression: a review
|Biomarker Research|2020|1.2k